Finland Will Execute the World’s Largest Osteoporosis Status Screening for Women - Boneindex
Finland Will Execute the World’s Largest Osteoporosis Status Screening for Women

One of Europe’s top new manufacturers of medical devices, Bone Index Ltd., joins forces with Suomen Terveystalo, Finland’s largest private health care provider. Together the two will screen 10 000 Finnish women with Bindex®, world’s first pocket-sized diagnostic device for osteoporosis, and provide them with accurate information about their osteoporosis status. This will change the way osteoporosis is diagnosed all over the world. 

Finland is the perfect test ground for Bindex®. Even though the quality of health care in Finland is top-notch compared to other OECD countries, only app. 10% of osteoporotic patients get the treatment they need. “Bindex® will change that for good,” says Bone Index’s CEO, Dr. Ossi Riekkinen.

10 000 women will be screened for osteoporosis in the beginning of 2017. “This is large percentage of the Finnish population. In US it would mean that we would screen 600 000 women in few months,” continues Dr. Riekkinen.

Undiagnosed osteoporosis is a worldwide challenge. In the USA alone osteoporosis is responsible for two million broken bones every year, costing over 19 billion dollars. Experts forecast that by 2025, the costs will rise to 25.3 billion dollars. One of the biggest challenges is the low availability of osteoporosis diagnostics. “This is why Bindex® is such a game-changer,” Dr. Riekkinen concludes.

Suomen Terveystalo’s Senior VP Susanna Kinnari agrees: “We have over 150 clinics and the most DXA devices in Finland. We believe that with Bindex® we will significantly improve the quality of care and provide higher accessibility to this extremely important service than ever before. This is also a great way to disseminate information on osteoporosis and its prevention and treatment. World Osteoporosis Day 20th October is great day to start this new era in osteoporosis diagnosis.”

For more information:
Bone Index Ltd., Dr. Ossi Riekkinen, CEO, , +358-50-363-2797,

‹ Back to the news page